Advertisement

Journal of Neurology

, Volume 265, Issue 11, pp 2594–2601 | Cite as

Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial

  • Rituparna Maiti
  • Biswa Ranjan Mishra
  • Monalisa Jena
  • Archana Mishra
  • Santanu Nath
  • Anand Srinivasan
Original Communication
  • 50 Downloads

Abstract

Purpose

S100B, a cytokine produced by astrocytes, has been studied as a biomarker of glial and neuronal damage in epilepsy. The present study investigated the reliability of serum S100B as a biomarker and the effect of carbamazepine and oxcarbazepine on serum S100B in patients with focal seizure.

Methods

The present randomized, open-label, active-controlled, parallel design clinical trial (NCT02705768) conducted on 60 patients with focal seizure. After recruitment, clinical evaluations were performed including Chalfont-National Hospital seizure severity scale (NHS3), Quality of Life in Epilepsy Inventory (QOLIE-31) and serum S100B was estimated. Thirty healthy individuals were recruited for evaluation of serum S100B at baseline only. After randomization, the study groups received either tablet oxcarbazepine or tablet carbamazepine. At follow-up after 2 weeks, clinical status was checked and at 4 weeks, NHS3 and QOLIE-31 were scored along with serum S100B level estimation.

Results

Serum S100B level in patients with focal seizure increased significantly in comparison to healthy volunteers. The decrease in serum S100B was significantly higher with carbamazepine group (0.004; 95% CI 0.001–0.006; p = 0.01) over oxcarbazepine group. In logistic regression analysis, there was an increase in the log odds of 0.17 for focal seizure positivity against healthy controls if S100B level increases by 1 pg and area under curve obtained by ROC analysis was 0.96 (p < 0.001).

Conclusion

Serum S100B increases in the patients with focal seizure and therapy with carbamazepine can decrease serum S100B level significantly over oxcarbazepine. Serum S100B can be used as a prognostic biomarker in a focal seizure.

Keywords

Focal seizure S100B Carbamazepine Oxcarbazepine 

Notes

Funding

None.

Compliance with ethical standards

Conflicts of interest

None to declare.

Ethical standards

The present study have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

References

  1. 1.
    Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, Haydon PG, Coulter DA (2010) Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci 13(5):584–591.  https://doi.org/10.1038/nn.2535 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60(6):614–632.  https://doi.org/10.1002/jemt.10303 CrossRefPubMedGoogle Scholar
  3. 3.
    Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33(7):637–668CrossRefGoogle Scholar
  4. 4.
    Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ (2000) Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31(11):2670–2677CrossRefGoogle Scholar
  5. 5.
    Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T (2001) S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 18(5):491–498.  https://doi.org/10.1089/089771501300227297 CrossRefPubMedGoogle Scholar
  6. 6.
    Lins H, Wallesch CW, Wunderlich MT (2005) Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurol Scand 112(5):303–308.  https://doi.org/10.1111/j.1600-0404.2005.00484.x CrossRefPubMedGoogle Scholar
  7. 7.
    Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR (2005) Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation 65(1):49–55.  https://doi.org/10.1016/j.resuscitation.2004.10.011 CrossRefPubMedGoogle Scholar
  8. 8.
    Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J (2007) Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38(9):2491–2495.  https://doi.org/10.1161/STROKEAHA.106.480111 CrossRefPubMedGoogle Scholar
  9. 9.
    Kleindienst A, Hesse F, Bullock MR, Buchfelder M (2007) The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 161:317–325.  https://doi.org/10.1016/S0079-6123(06)61022-4 CrossRefPubMedGoogle Scholar
  10. 10.
    Nash DL, Bellolio MF, Stead LG (2008) S100 as a marker of acute brain ischemia: a systematic review. Neurocritical Care 8(2):301–307.  https://doi.org/10.1007/s12028-007-9019-x CrossRefPubMedGoogle Scholar
  11. 11.
    Geyer C, Ulrich A, Grafe G, Stach B, Till H (2009) Diagnostic value of S100B and neuron-specific enolase in mild pediatric traumatic brain injury. J Neurosurg Pediatr 4(4):339–344.  https://doi.org/10.3171/2009.5.PEDS08481 CrossRefPubMedGoogle Scholar
  12. 12.
    Sandler SJ, Figaji AA, Adelson PD (2010) Clinical applications of biomarkers in pediatric traumatic brain injury. Child’s Nerv Syst 26(2):205–213.  https://doi.org/10.1007/s00381-009-1009-1 CrossRefGoogle Scholar
  13. 13.
    Steinhoff BJ, Tumani H, Otto M, Mursch K, Wiltfang J, Herrendorf G, Bittermann HJ, Felgenhauer K, Paulus W, Markakis E (1999) Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res 36(1):75–82CrossRefGoogle Scholar
  14. 14.
    Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M, Kubik A, Basta-Kaim A (2012) Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep PR 64(6):1427–1433CrossRefGoogle Scholar
  15. 15.
    Chang CC, Lui CC, Lee CC, Chen SD, Chang WN, Lu CH, Chen NC, Chang AY, Chan SH, Chuang YC (2012) Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol 12:15.  https://doi.org/10.1186/1471-2377-12-15 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lu C, Li J, Sun W, Feng L, Li L, Liu A, Li J, Mao W, Wei H, Gao L, Zhang X, Huang Z, Meng X, Wang Y (2010) Elevated plasma S100B concentration is associated with mesial temporal lobe epilepsy in Han Chinese: a case–control study. Neurosci Lett 484(2):139–142.  https://doi.org/10.1016/j.neulet.2010.08.036 CrossRefPubMedGoogle Scholar
  17. 17.
    Mikkonen K, Pekkala N, Pokka T, Romner B, Uhari M, Rantala H (2012) S100B proteins in febrile seizures. Seizure 21(2):144–146.  https://doi.org/10.1016/j.seizure.2011.10.006 CrossRefPubMedGoogle Scholar
  18. 18.
    Leutmezer F, Wagner O, Baumgartner C (2002) Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsy. Epilepsia 43(10):1172–1174CrossRefGoogle Scholar
  19. 19.
    Portela LV, Tort AB, Walz R, Bianchin M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO (2003) Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy. Acta Neurol Scand 108(6):424–427CrossRefGoogle Scholar
  20. 20.
    Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685.  https://doi.org/10.1111/j.1528-1167.2010.02522.x CrossRefPubMedGoogle Scholar
  21. 21.
    Duncan JS, Sander JW (1991) The chalfont seizure severity scale. J Neurol Neurosurg Psychiatry 54(10):873–876CrossRefGoogle Scholar
  22. 22.
    Cramer JA, French J (2001) Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components. Epilepsia 42(1):119–129CrossRefGoogle Scholar
  23. 23.
    Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B (1998) Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39(1):81–88CrossRefGoogle Scholar
  24. 24.
    Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinform 12:77.  https://doi.org/10.1186/1471-2105-12-77 CrossRefGoogle Scholar
  25. 25.
    Khurgel M, Ivy GO (1996) Astrocytes in kindling: relevance to epileptogenesis. Epilepsy Res 26(1):163–175CrossRefGoogle Scholar
  26. 26.
    Jankowsky JL, Patterson PH (2001) The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 63(2):125–149CrossRefGoogle Scholar
  27. 27.
    Donato R (1999) Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochimica et Biophysica Acta 1450(3):191–231CrossRefGoogle Scholar
  28. 28.
    Goncalves DS, Lenz G, Karl J, Goncalves CA, Rodnight R (2000) Extracellular S100B protein modulates ERK in astrocyte cultures. Neuroreport 11(4):807–809CrossRefGoogle Scholar
  29. 29.
    Wong CH, Rooney SJ, Bonser RS (1999) S-100beta release in hypothermic circulatory arrest and coronary artery surgery. Ann Thorac Surg 67(6):1911–1914 (discussion 1919–1921) CrossRefGoogle Scholar
  30. 30.
    Lubrich B, van Calker D (1999) Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21(4):519–529.  https://doi.org/10.1016/S0893-133X(99)00037-8 CrossRefPubMedGoogle Scholar
  31. 31.
    Song D, Du T, Li B, Cai L, Gu L, Li H, Chen Y, Hertz L, Peng L (2008) Astrocytic alkalinization by therapeutically relevant lithium concentrations: implications for myo-inositol depletion. Psychopharmacology 200(2):187–195.  https://doi.org/10.1007/s00213-008-1194-8 CrossRefPubMedGoogle Scholar
  32. 32.
    Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L (2000) Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Res 855(1):158–161CrossRefGoogle Scholar
  33. 33.
    Li B, Gu L, Zhang H, Huang J, Chen Y, Hertz L, Peng L (2007) Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific. Psychopharmacology 194(3):333–345.  https://doi.org/10.1007/s00213-007-0853-5 CrossRefPubMedGoogle Scholar
  34. 34.
    Li B, Zhang S, Li M, Zhang H, Hertz L, Peng L (2009) Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 57(4):375–385.  https://doi.org/10.1016/j.neuropharm.2009.07.004 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Rituparna Maiti
    • 1
  • Biswa Ranjan Mishra
    • 2
  • Monalisa Jena
    • 1
  • Archana Mishra
    • 1
  • Santanu Nath
    • 2
  • Anand Srinivasan
    • 1
  1. 1.Department of PharmacologyAll India Institute of Medical Sciences (AIIMS)BhubaneswarIndia
  2. 2.Department of PsychiatryAll India Institute of Medical Sciences (AIIMS)BhubaneswarIndia

Personalised recommendations